NCT06785324
- Conditions
- B Cell Acute Lymphoblastic Leukemia (B-ALL), B-ALL, Burkitt Lymphoma, +17 more
- Locations
-
- University of Chicago Medicine Comprehensive Cancer Center Chicago, Illinois, United States
Clinical trial condition
B-ALL
Explore clinical trials studying B-ALL. Study availability and eligibility vary by location and protocol.
28 public trials
14 recruiting studies
B-ALL trial results
Recruiting
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
NCT06911710
- Conditions
- AML (Acute Myelogenous Leukemia), B-ALL, Blood Protein Disorders, +23 more
- Locations
-
- TianJin China. TianJin Medical University General Tianjin, Tianjin Municipality, China
Recruiting
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
NCT04781634
- Conditions
- B-ALL
- Locations
-
- 920th Hospital of Joint Logistics Support Force Kunming, Yunnan, China
Recruiting
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia
NCT06678282
- Conditions
- B-ALL, B-NHL
- Locations
-
- The First Affiliated Hospital of Zhengzhou University Zhenzhou, Henan, China
NCT07572136
- Conditions
- Acute Lymphoblastic Leukemia, B-ALL, Hematologic Diseases, +10 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
Not Yet Recruiting
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
NCT07313852
- Conditions
- B-ALL, B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Acute Lymphoblastic Leukemia, +17 more
- Locations
-
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) New York, United States
Not Yet Recruiting
JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia
NCT06902025
- Conditions
- B-ALL
- Locations
-
- The First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou, Zhejiang, China
Not Yet Recruiting
Blinatumomab as Maintenance Therapy in Patients With High-risk B-lineage Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation
NCT06658938
- Conditions
- B-ALL
- Locations
-
Not specified
Not Yet Recruiting
The Use of Blinatumomab in Patients With NGS-MRD Relapsed B-ALL After Autologous/Allogeneic Transplantation
NCT06504186
- Conditions
- B-ALL
- Locations
-
Not specified
NCT02315612
- Conditions
- ALL, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, +32 more
- Locations
-
- National Institutes of Health Clinical Center Bethesda, Maryland, United States